Knight Therapeutics Inc. (GUD.TO)
CAD 6.17
(0.65%)
CAD 6.17
(0.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 155.54 Million CAD | -34.77% |
| 2022 | 155.12 Million CAD | 20.96% |
| 2021 | 128.24 Million CAD | 14.82% |
| 2020 | 111.69 Million CAD | 182.22% |
| 2019 | 39.57 Million CAD | 147.68% |
| 2018 | 15.97 Million CAD | 0.14% |
| 2017 | 15.95 Million CAD | 30.5% |
| 2016 | 12.22 Million CAD | 2.59% |
| 2015 | 11.91 Million CAD | 120.8% |
| 2014 | 5.39 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 31.16 Million CAD | 10.66% |
| 2024 Q1 | 28.16 Million CAD | 21.79% |
| 2023 Q2 | 37.6 Million CAD | 7.04% |
| 2023 FY | 101.18 Million CAD | -34.77% |
| 2023 Q4 | 23.12 Million CAD | -41.08% |
| 2023 Q3 | 39.25 Million CAD | 4.39% |
| 2023 Q1 | 35.12 Million CAD | -23.69% |
| 2022 Q2 | 35.95 Million CAD | 9.65% |
| 2022 FY | 155.12 Million CAD | 20.96% |
| 2022 Q4 | 46.03 Million CAD | 14.13% |
| 2022 Q3 | 40.33 Million CAD | 12.17% |
| 2022 Q1 | 32.79 Million CAD | -23.43% |
| 2021 Q2 | 28.85 Million CAD | 26.47% |
| 2021 Q1 | 22.81 Million CAD | -28.16% |
| 2021 Q4 | 42.82 Million CAD | 26.92% |
| 2021 FY | 128.24 Million CAD | 14.82% |
| 2021 Q3 | 33.74 Million CAD | 16.95% |
| 2020 Q2 | 25.34 Million CAD | -7.23% |
| 2020 FY | 111.69 Million CAD | 182.22% |
| 2020 Q3 | 27.26 Million CAD | 7.59% |
| 2020 Q4 | 31.75 Million CAD | 16.46% |
| 2020 Q1 | 27.32 Million CAD | 35.24% |
| 2019 Q2 | 6.57 Million CAD | 17.59% |
| 2019 Q1 | 5.59 Million CAD | 24.23% |
| 2019 Q4 | 20.2 Million CAD | 180.49% |
| 2019 FY | 39.57 Million CAD | 147.68% |
| 2019 Q3 | 7.2 Million CAD | 9.49% |
| 2018 FY | 15.97 Million CAD | 0.14% |
| 2018 Q4 | 4.5 Million CAD | 19.13% |
| 2018 Q2 | 3.86 Million CAD | 0.91% |
| 2018 Q1 | 3.83 Million CAD | 3.23% |
| 2018 Q3 | 3.78 Million CAD | -2.2% |
| 2017 Q3 | 4.1 Million CAD | -10.07% |
| 2017 Q2 | 4.56 Million CAD | 27.79% |
| 2017 Q1 | 3.57 Million CAD | -7.15% |
| 2017 FY | 15.95 Million CAD | 30.5% |
| 2017 Q4 | 3.71 Million CAD | -9.64% |
| 2016 FY | 12.22 Million CAD | 2.59% |
| 2016 Q1 | 2.52 Million CAD | 18.49% |
| 2016 Q4 | 3.84 Million CAD | 28.78% |
| 2016 Q2 | 2.86 Million CAD | 13.47% |
| 2016 Q3 | 2.98 Million CAD | 4.29% |
| 2015 Q3 | 3.97 Million CAD | 43.08% |
| 2015 Q4 | 2.13 Million CAD | -46.34% |
| 2015 FY | 11.91 Million CAD | 120.8% |
| 2015 Q1 | 3.03 Million CAD | 20.34% |
| 2015 Q2 | 2.77 Million CAD | -8.7% |
| 2014 Q4 | 2.52 Million CAD | 30.19% |
| 2014 Q3 | 1.94 Million CAD | 133.33% |
| 2014 Q2 | 831.58 Thousand CAD | 738.91% |
| 2014 Q1 | 99.12 Thousand CAD | 0.0% |
| 2014 FY | 5.39 Million CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | 545.21 Thousand CAD | 0.0% |
| 2012 Q3 | 335.03 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aurora Cannabis Inc. | 158.53 Million CAD | 1.89% |
| Avicanna Inc. | 14.59 Million CAD | -965.962% |
| Avant Brands Inc. | 5.65 Million CAD | -2648.577% |
| Cardiol Therapeutics Inc. | 29.53 Million CAD | -426.598% |
| Crescita Therapeutics Inc. | 12.32 Million CAD | -1162.516% |
| MediPharm Labs Corp. | 23.08 Million CAD | -573.838% |
| OrganiGram Holdings Inc. | 277.81 Million CAD | 44.012% |
| Canopy Growth Corporation | 308.61 Million CAD | 49.599% |
| Willow Biosciences Inc. | 7.55 Million CAD | -1959.068% |
| Auxly Cannabis Group Inc. | 40.28 Million CAD | -286.133% |